ASCPT 2024 Annual Meeting
Is Pharmacogenetic Testing a Vital Tool for Enhancing Therapeutic Management of Patients Worldwide?
CHAIR: Piet van der Graaf, PhD, PharmD
|Senior Vice President and Head of Quantitative Systems Pharmacology
Transporter Research for Global Outreach: Unleashing the Power of Everything, Everywhere, All at Once
Sibylle Neuhoff, PhD
|Sr. Principal Scientist and Deputy Head of Translational Science
Certara CDDS Lunch & Learn @ ASCPT ‘24: Bespoke Comprehensive Cardiac Safety Support at Certara and Recent Experience with C-QTc modeling in Special Populations
Certara will provide an overview of available Cardiac Assessment support, highlighting a comprehensive range of expertise from a team of clinical pharmacologists and pharmacometricians along an with experienced toxicologist and a cardiologist. A range of offerings are available ranging from QTc assessment and waiver strategies to modeling offerings that can be customized to development milestones, ranging from concentration (C)-QTc feasibility, exploratory C-QTc analysis to full C-QTc analysis suitable to support Regulatory submissions. In addition, broader support available for Healthy Authority Submissions and Communications, with recent experience with integrated assessment of both nonclinical and clinical cardiac safety data will be shared, as well as recent experience, including C-QTc modeling in special populations.
-
Amy Cheung, PhD, Vice President, Certara Drug Development Solutions
-
Mark Shelton, PharmD, Vice President, Clinical Pharmacology, Certara Drug Development Solutions
Unleashing Your Leadership Potential via Volunteering and Networking within ASCPT: A Journey of Growth
Karen Rowland Yeo, PhD
|Senior Vice President, Client & Regulatory Strategy
Wheel of (Mis)Fortune: Global Partnerships to Tackle Pediatric Infectious Diseases
CHAIR: Amy Cheung, PhD
|Vice President, Certara Drug Development Solutions
Expanding Regulatory Science: Regulatory Complementarity & Reliance
David Wesche, MD, PhD
|Vice President Clinical Pharmacology
Certara QSP Lunch & Learn @ ASCPT ‘24: QSP-Enabled FIH Study in Oncology: Saving Clinical Development and Patient Time
-
QSP: A mechanistic modeling approach aiding research groups in de-risking and bolstering confidence in therapeutic development decisions.
-
Certara’s acquisition of Applied BioMath aims to industrialize QSP for broader adoption and impact in therapeutic R&D.
-
Demonstrating a pipeline example showcasing QSP’s potential for approximately 10x ROI, with the capacity for 100x ROI across large portfolios.
-
Real-world examples illustrating the tangible impact of QSP on first-in-man study design.
When AI Meets Drug Development
Mark Sale, MD
|Vice President, IDD
Certara Poster Presenters
- Bryan Holland, PhD
- Udoamaka Ezuruike, PhD
- Lisa Almond, PhD
- Xian Pan, PhD
- Kimiko McGirr, PhD